RxDoctor Payments Data

Marc Sintek, MD

Interventional Cardiology · Saint Louis, MONPI 1700049129

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (44.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Philips North America LLC at 39.0% of the total. Among interventional cardiology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$118,717in general payments, 2019–2025

Across 384 payments — averaging $309.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$46K
  • Edwards Lifesciences$41K
  • Shockwave Medical, Inc$13K
  • Boston Scientific$7K
  • Biotronik Inc.$6K
  • Abiomed$2K
  • plus $4K from 13 others
$488,513in research payments, 2019–2025

Across 59 payments — averaging $8279.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$206K
  • Boston Scientific$171K
  • Abbott$56K
  • Philips North America LLC$55K

What the payments were for

  • Consulting fees$52,75144%
  • Speaking & faculty fees$35,73330%
  • Travel & lodging$10,6489%
  • Food & beverage$19,56916%
  • Education$160%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$118,717 in reported general payments places this provider in the 90th percentile of 182 interventional cardiology providers in Missouri.

See all interventional cardiology providers in Missouri

Medicare billing

Part B allowed, 2024
$174,812
Medicare patients
427
Services billed
1,084

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban177$199,118
EntrestoSacubitril/Valsartan118$124,933
XareltoRivaroxaban14$21,604
JardianceEmpagliflozin22$15,840
Repatha SureclickEvolocumab12$8,909
Ranolazine ErRanolazine30$3,770
Metoprolol Succinate178$1,927
Atorvastatin Calcium154$1,714
Rosuvastatin Calcium110$1,315
Carvedilol95$1,099
Isosorbide Mononitrate ErIsosorbide Mononitrate57$1,093
Amlodipine Besylate132$1,058
ClopidogrelClopidogrel Bisulfate124$977
Bumetanide24$854
Spironolactone125$781

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →